CordenPharma and Viking Forge Partnership for GLP-1 Drug Candidate VK2735

Full-service CDMO, CordenPharma, and clinical-stage biopharmaceutical company, Viking Therapeutics, have entered a multi-year strategic partnership to support the development and commercialization of Viking's GLP-1 drug candidate, VK2735 to encompass large-scale peptide manufacturing of the dual GLP-1/GIP receptor agonist drug substance, fill-finish services for its subcutaneous formulation, and oral solid dosage manufacturing for its oral peptide formulation.

VK2735 is currently under investigation as a potential treatment for metabolic disorders, including obesity. In February 2025, Viking reported positive Phase IIa results, demonstrating significant reductions in body weight after 13 weeks of treatment.

CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the signing of a strategic partnership with Viking Therapeutics, Inc., a clinical-stage company focused on developing novel therapies for metabolic and endocrine disorders. Under this multi-year supply contract, CordenPharma provides development and manufacturing services for clinical and commercial demand of Viking Therapeutics’ GLP-1 drug candidate VK2735, a Dual GLP-1/GIP Receptor Agonist, across the full supply chain from drug substance to drug product for both its subcutaneous and oral peptide formulations.

CordenPharma is committed to ensuring seamless development and commercialization of Viking Therapeutics’ VK2735 drug candidate by leveraging its global network of advanced manufacturing facilities for drug substance, fill-finish and oral solid dosage finished product.

This uniquely integrated capability incorporates CordenPharma’s extensive experience in large-scale peptide drug substance, sterile injectable fill-finish, and oral solid dosage manufacturing. With built-in redundancy through multiple drug substance sites across its global facility network, CordenPharma is well-positioned to ensure a secure and uninterrupted supply chain throughout the lifecycle of Viking Therapeutics’ VK2735 drug candidate.

Dr. Michael Quirmbach, President & CEO of the CordenPharma Group, comments: “We are proud to support Viking Therapeutics with a strong end-to-end offering for their complex modalities, from peptide drug substance to drug product, for this innovative VK2735 drug candidate. Our global teams are excited to provide true integration of our expertise across the pharma supply chain to meet the increasing demand for GLP-1 peptide therapeutics and ultimately, improve patient outcomes.”

For more, please find the original story source here.